Dago Dougba Noel, Scafoglio Claudio, Rinaldi Antonio, Memoli Domenico, Giurato Giorgio, Nassa Giovanni, Ravo Maria, Rizzo Francesca, Tarallo Roberta, Weisz Alessandro
Laboratory of Molecular Medicine and Genomics, Department of Medicine and Surgery, University of Salerno, Via S. Allende, 1, Baronissi, SA, 84081, Italy.
UFR Sciences Biologiques, Université Peleforo Gon Coulibaly, Korhogo, Ivory Coast.
BMC Genomics. 2015 May 9;16(1):367. doi: 10.1186/s12864-015-1541-1.
Estrogens play an important role in breast cancer (BC) development and progression; when the two isoforms of the estrogen receptor (ERα and ERβ) are co-expressed each of them mediate specific effects of these hormones in BC cells. ERβ has been suggested to exert an antagonist role toward the oncogenic activities of ERα, and for this reason it is considered an oncosuppressor. As clinical evidence regarding a prognostic role for this receptor subtype in hormone-responsive BC is still limited and conflicting, more knowledge is required on the biological functions of ERβ in cancer cells. We have previously described the ERβ and ERα interactomes from BC cells, identifying specific and distinct patterns of protein interactions for the two receptors. In particular, we identified factors involved in mRNA splicing and maturation as important components of both ERα and ERβ pathways. Guided by these findings, here we performed RNA sequencing to investigate in depth the differences in the early transcriptional events and RNA splicing patterns induced by estradiol in cells expressing ERα alone or ERα and ERβ.
Exon skipping was the most abundant splicing event in the post-transcriptional regulation by estradiol. We identified several splicing events induced by ERα alone and by ERα+ERβ, demonstrating for the first time that ERβ significantly affects estrogen-induced splicing in BC cells, as revealed by modification of a subset of ERα-dependent splicing by ERβ, as well as by the presence of splicing isoforms only in ERβ+cells. In particular, we observed that ERβ+BC cell lines exhibited around 2-fold more splicing events than the ERβ- cells. Interestingly, we identified putative direct targets of ERβ-mediated alternative splicing by correlating the genomic locations of ERβ and ERα binding sites with estradiol-induced differential splicing in the corresponding genes.
Taken together, these results demonstrate that ERβ significantly affects estrogen-induced early transcription and mRNA splicing in hormone-responsive BC cells, providing novel information on the biological role of ERβ in these tumors.
雌激素在乳腺癌(BC)的发生和发展中起重要作用;当雌激素受体的两种异构体(ERα和ERβ)共表达时,它们各自介导这些激素在BC细胞中的特定作用。有人提出ERβ对ERα的致癌活性发挥拮抗作用,因此它被认为是一种肿瘤抑制因子。由于关于该受体亚型在激素反应性BC中的预后作用的临床证据仍然有限且相互矛盾,因此需要更多关于ERβ在癌细胞中的生物学功能的知识。我们之前已经描述了BC细胞中的ERβ和ERα相互作用组,确定了两种受体特异性和独特的蛋白质相互作用模式。特别是,我们确定参与mRNA剪接和成熟的因子是ERα和ERβ途径的重要组成部分。基于这些发现,我们在此进行了RNA测序,以深入研究单独表达ERα或同时表达ERα和ERβ的细胞中雌二醇诱导的早期转录事件和RNA剪接模式的差异。
外显子跳跃是雌二醇转录后调控中最丰富的剪接事件。我们确定了几种仅由ERα和由ERα + ERβ诱导的剪接事件,首次证明ERβ显著影响BC细胞中雌激素诱导的剪接,这通过ERβ对一部分ERα依赖性剪接的修饰以及仅在ERβ +细胞中存在剪接异构体得以揭示。特别是,我们观察到ERβ + BC细胞系的剪接事件比ERβ -细胞多约2倍。有趣的是,通过将ERβ和ERα结合位点的基因组位置与相应基因中雌二醇诱导的差异剪接相关联,我们确定了ERβ介导的选择性剪接的推定直接靶点。
综上所述,这些结果表明ERβ显著影响激素反应性BC细胞中雌激素诱导的早期转录和mRNA剪接,为ERβ在这些肿瘤中的生物学作用提供了新信息。